FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.

Christina Schaub,Susanne Greschus,M. Seifert,Andreas Waha,Elias Blasius,Katja Rasch,Christiane Landwehr,Frederic Mack,Niklas Schäfer,Moritz Stuplich,Sied Kebir,Belinda Vilz,Björn Scheffler,Jan Boström,Matthias Simon,Horst Urbach,Martin Glas,Ulrich Herrlinger

FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.

2013

Christina Schaub
Susanne Greschus
M. Seifert
Andreas Waha
Elias Blasius
Katja Rasch
Christiane Landwehr
Frederic Mack
Niklas Schäfer
Moritz Stuplich
Sied Kebir
Belinda Vilz
Björn Scheffler
Jan Boström
Matthias Simon
Horst Urbach
Martin Glas
Ulrich Herrlinger

Objectives: In this study, we analyzed the prognostic value of different MRI progression patterns for survival in patients with recurrent malignant glioma treated

Keywords:

Pathology
Bevacizumab
Glioblastoma
Glioma
Medicine
Oncology
Fluid-attenuated inversion recovery
short survival
Internal medicine
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations